TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

MEM SLOAN-KETTERING

CardiovascularMetabolicOphthalmology
Generics

MEM SLOAN-KETTERING is a generic drug manufacturer focused on Cardiovascular, Metabolic, Ophthalmology.

2016
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 49%
0 drugs Phase 3: 10 Phase 2: 1
Metabolic 38%
0 drugs Phase 3: 8
Ophthalmology 7%
0 drugs Phase 3: 1 Phase 2: 1
Dermatology 5%
0 drugs Phase 3: 1
Immunology 1%
0 drugs Phase 1: 1

Pipeline Strength Pro

Loading...